Jonathan Binder, MD
Family Medicine · Casper, WYNPI 1841214954
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $916 and has fallen 70.8% since, to $267 in 2025. Among family medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$787
- AbbVie$737
- GSK$717
- Lilly USA, LLC$318
- Merck$176
- Novo Nordisk$170
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,12398%
- Education$140%
- Other$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $787 |
| AbbVie | 33 | $737 |
| GSK | 40 | $717 |
| Lilly USA, LLC | 21 | $318 |
| Merck | 10 | $176 |
| Novo Nordisk | 10 | $170 |
| Lundbeck LLC | 7 | $137 |
| Pfizer | 8 | $126 |
| Amgen | 6 | $96 |
| Novartis | 5 | $93 |
| Baxter Healthcare | 1 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Amarin Pharma, Inc. | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 8 | $60 |
| Axsome Therapeutics, Inc. | 1 | $48 |
| Boehringer Ingelheim | 3 | $44 |
| Dexcom, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $38 |
| Digestive Care, Inc. | 2 | $37 |
| Optinose US, Inc. | 2 | $35 |
| Abbott | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Viatris Specialty LLC | 1 | $28 |
| Mylan Specialty L.p. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| Biogen | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,224 in reported general payments places this provider in the 95th percentile of 237 family medicine providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 104 | $119,983 |
| OzempicSemaglutide | 95 | $92,828 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $69,167 |
| TrulicityDulaglutide | 43 | $62,482 |
| JardianceEmpagliflozin | 30 | $45,058 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $36,807 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $32,278 |
| MyrbetriqMirabegron | 22 | $29,242 |
| FarxigaDapagliflozin Propanediol | 19 | $24,694 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $18,011 |
| XareltoRivaroxaban | 30 | $14,772 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $12,801 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $12,090 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $11,505 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $119,983104 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $717 | $94,452167 claims |
| Novo NordiskOzempic | $170 | $92,82895 claims |
| Lilly USA, LLCTrulicity | $318 | $62,48243 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $44 | $57,85955 claims |
| MerckJanumet | $176 | $32,27831 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $29,24222 claims |
| AstraZenecaFarxiga | $787 | $24,69419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 family medicine providers in Wyoming.
Other family medicine in Casper
- Joseph SchoeberCasper$176K
- James McLennanCasper$13K
- Karlynn SieversCasper$10K
- Eric LawrenceCasper$7K
- Louis RoussalisCasper$5K
- Joseph MickelsonCasper$5K
- Sherrill FoxCasper$4K
- Taylor PedersenCasper$4K
- Tiffany SpauldingCasper$2K
- Brehan NewellCasper$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.